Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

2019141 citationsJournal Articlehybrid Open Access

Authors

Michael J. Koren · Jacksonville University

Marc S. Sabatine · Brigham and Women's Hospital

Robert P. Giugliano · Brigham and Women's Hospital

Gisle Langslet · Oslo University Hospital

Stephen D. Wiviott · Thrombolysis in Myocardial Infarction Study Group

Andrea Ruzza · Amgen (United States)

Yuhui Ma

Abstract

The OSLER-1 trial demonstrated consistently excellent LDL-C-lowering efficacy, tolerance, and safety of evolocumab, with no neutralizing antibodies detected, throughout the longest-duration study of a PCSK9 inhibitor reported to date. (Open Label Study of Long Term Evaluation Against LDL-C Trial [OSLER-1]; NCT01439880).

Topics & Keywords

Lipoproteins and Cardiovascular Health Biosimilars and Bioanalytical Methods Pharmaceutical Economics and Policy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the American College of Cardiology

Volume 74, Issue 17, pp. 2132-2146

DOI: 10.1016/j.jacc.2019.08.1024

Field-Weighted Citation Impact: 18.80